Industry Leaders Launch Keystone LifeSci Collaborative, a New Partnership to Support Southeastern Pennsylvania’s Life Science Sector First sector partnership of its kind convenes life sciences companies from across six counties [….]
Arbutus: Hunting a Functional Cure for Chronic Hepatitis B Infection By Mark TerryMay 5, 2023 Arbutus Biopharma, based in Warminster, Penn. is moving closer to achieving its goal of developing [….]
Polysciences, Inc., a Pennsylvania-based manufacturer of specialty chemicals for research, IVD and medical device applications, has announced its plan to create a new brand, Kyfora Bio, representing its product offerings to the bioprocessing market.
Life Sciences PA today announced its headquarters will be moving from its current location on Swedesford Rd. in Wayne to 411 Swedeland Road in King of Prussia, PA. The
expanded space and rising hub of life sciences in southeastern PA will be the Association’s new home
beginning February 2022.
Chimeric Antigen Receptor T cell (CAR-T) therapies, such as those developed by Kite Pharma, have revolutionized the approach to treating hematological cancers, but the therapies have limitations due to toxicity concerns. Pennsylvania-based BlueSphere Bio believes its approach through the use of TCR-T cell therapies will provide a more precise treatment option for patients.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Jonathan J. Birchall as Chief Commercial Officer.
Neil Sheppard is an Immunologist educated in the UK at the Universities of Bristol and Oxford. He has over 18 years’ experience in the fields of vaccines and immunotherapies, including over a dozen years leading drug discovery and development programs in Big Pharma and Biotech.
